Macquarie Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Macquarie Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,585	Closed	-$32K	–	2670
2021 Q3	$32K	Hold	1,585	–	–	﹤0.01%	2350
2021 Q2	$59K	Sell	1,585 -285	-15%	-$8.73K	﹤0.01%	2128
2021 Q1	$48K	Sell	1,870 -573	-23%	-$14.6K	﹤0.01%	2091
2020 Q4	$54K	Hold	2,443	–	–	﹤0.01%	2023
2020 Q3	$44K	Hold	2,443	–	–	﹤0.01%	1984
2020 Q2	$62K	Buy	+2,443	New	+$52.6K	﹤0.01%	1881
2019 Q1	–	Sell	-200	Closed	-$2K	–	2189
2018 Q4	$2K	Sell	200 -200	-50%	-$2.63K	﹤0.01%	2211
2018 Q3	$6K	Buy	+400	New	+$5.82K	﹤0.01%	2055

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Macquarie Group's DRNA Position: Q4 2021 in Review

Macquarie Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,585 shares — an estimated $32K sold.

Macquarie Group first reported a position in DRNA in Q3 2018 and held it in 8 quarters. The position peaked at $62K in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Macquarie Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Macquarie Group sold 1,585 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $32K.
Macquarie Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 8 quarters.
Macquarie Group's Dicerna Pharmaceuticals, Inc. position peaked at $62K in Q2 2020.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Macquarie Group's 13F filing for Q4 2021, filed 11 Feb 2022.